Increased antiangiogenic protein expression in the skeletal muscle of diabetic swine and patients

Archives of Surgery

Volumn 143, Issue 5, 2008, Pages 463-470

  Sodha, Neel R ^a   Boodhwani, Munir ^a   Clements, Richard T ^a   Xu, Shu Hua ^a   Khabbaz, Kamal R ^a   Sellke, Frank W ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; COLLAGEN TYPE 18; ENDOSTATIN; GELATINASE A; GELATINASE B; MUSCLE PROTEIN; PLASMINOGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIABETIC PATIENT; ELECTIVE SURGERY; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKELETAL MUSCLE; SWINE; WESTERN BLOTTING; ZYMOGRAPHY;

AGED; ANGIOSTATINS; ANIMALS; CASE-CONTROL STUDIES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; ENDOSTATINS; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MUSCLE, SKELETAL; SWINE; SWINE, MINIATURE;

EID: 44149123129     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.143.5.463     Document Type: Article

References (49)

1. National Institutes of Health. National diabetes statistics. http://diabetes.niddk.nih.gov/dm/pubs/statistics/. Accessed February 25, 2007.
2. Grundy SM, Garber A, Goldberg R, et al. Prevention conference VI: diabetes and cardiovascular disease: writing group IV: lifestyle and medical management of risk factors. Circulation. 2002;105(18):e153-e158.
3. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287(19):2570- 2581.
4. Kullo IJ, Bailey KR, Kardia SL, Mosley TH Jr, Boerwinkle E, Turner ST. Ethnic differences in peripheral arterial disease in the NHLBI Genetic Epidemiology Network of Arteriopathy (GENOA) study. Vasc Med. 2003;8(4):237-242.
5. Renard CB, Kramer F, Johansson F, et al. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest. 2004;114(5):659-668.
6. Bild DE, Selby JV, Sinnock P, Browner WS, Braveman P, Showstack JA. Lower-extremity amputation in people with diabetes: epidemiology and prevention. Diabetes Care. 1989;12(1):24-31.
7. Xie D, Li Y, Reed EA, Odronic SI, Kontos CD, Annex BH. An engineered vascular endothelial growth factor-activating transcription factor induces therapeutic angiogenesis in ApoE knockout mice with hindlimb ischemia. J Vasc Surg. 2006;44(1):166-175.
8. Isner JM, Pieczek A, Schainfeld R, et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet. 1996;348(9024):370-374.
9. Isner JM, Walsh K, Symes J, et al. Arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease. Hum Gene Ther. 1996;7(8):959-988.
10. Rajagopalan S, Trachtenberg J, Mohler E, et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication. Am J Cardiol. 2002;90(5):512-516.
11. Lazarous DF, Unger EF, Epstein SE, et al. Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. J Am Coll Cardiol. 2000;36(4):1239-1244.
12. Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of ph-VEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 1998;97(12):1114-1123.
13. Shyu KG, Chang H, Wang BW, Kuan P. Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. Am J Med. 2003;114(2):85-92.
14. Mohler ER III, Rajagopalan S, Olin JW, et al. Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trial. Vasc Med. 2003;8(1):9-13.
15. Comerota AJ, Throm RC, Miller KA, et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg. 2002;35(5):930-936.
16. Lederman RJ, Mendelsohn FO, Anderson RD, et al; TRAFFIC Investigators. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet. 2002;359(9323):2053-2058.
17. Rajagopalan S, Mohler E III, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: design of the RAVE trial. Am Heart J. 2003;145(6):1114-1118.
18. Abaci A, Oguzhan A, Kahraman S, et al. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation. 1999;99(17):2239-2242.
19. Weihrauch D, Lohr NL, Mraovic B, et al. Chronic hyperglycemia attenuates coronary collateral development and impairs proliferative properties of myocardial interstitial fluid by production of angiostatin. Circulation. 2004;109(19):2343-2348.
20. Boodhwani M, Sodha NR, Mieno S, et al. Insulin treatment enhances the myocardial angiogenic response in diabetes. J Thorac Cardiovasc Surg. 2007;134(6):1453-1460.
21. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994;79(2):315-328.
22. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88(2):277-285.
23. Matsunaga T, Chilian WM, March K. Angiostatin is negatively associated with coronary collateral growth in patients with coronary artery disease. Am J Physiol Heart Circ Physiol. 2005;288(5):H2042-H2046.
24. Panchal VR, Rehman J, Nguyen AT, et al. Reduced pericardial levels of endostatin correlate with collateral development in patients with ischemic heart disease. J Am Coll Cardiol. 2004;43(8):1383-1387.
25. Boodhwani M, Nakai Y, Mieno S, et al. Hypercholesterolemia impairs the myocardial angiogenic response in a swine model of chronic ischemia: role of endostatin and oxidative stress. Ann Thorac Surg. 2006;81(2):634-641.
26. National Research Council. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academies Press; 1996. NIH publication 5377-3 1996.
27. Rendell M, Stephen PM, Paulsen R, et al. An interspecies comparison of normal levels of glycosylated hemoglobin and glycosylated albumin. Comp Biochem Physiol B. 1985;81(4):819-822.
28. Jones WS, Annex BH. Growth factors for therapeutic angiogenesis in peripheral arterial disease. Curr Opin Cardiol. 2007;22(5):458-463.
29. Li Y, Hazarika S, Xie D, Pippen AM, Kontos CD, Annex BH. In mice with type 2 diabetes, a vascular endothelial growth factor (VEGF)-activating transcription factor modulates VEGF signaling and induces therapeutic angiogenesis after hindlimb ischemia. Diabetes. 2007;56(3):656-665.
30. Fadini GP, Miorin M, Facco M, et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol. 2005;45(9):1449-1457.
31. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002;2(10):727-739.
32. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29(6)(suppl 16):15-18.
33. Wahl ML, Kenan DJ, Gonzalez-Gronow M, Pizzo SV. Angiostatin's molecular mechanism: aspects of specificity and regulation elucidated. J Cell Biochem. 2005;96(2):242-261.
34. Moser TL, Stack MS, Asplin I, et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A. 1999;96(6):2811-2816.
35. Moser TL, Kenan DJ, Ashley TA, et al. Endothelial cell surface F1-F0 ATP syn-thase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci U S A. 2001;98(12):6656-6661.
36. Sharma MR, Tuszynski GP, Sharma MC. Angiostatin-induced inhibition of endothelial cell proliferation/apoptosis is associated with the down-regulation of cell cycle regulatory protein cdk5. J Cell Biochem. 2004;91(2):398-409.
37. Troyanovsky B, Levchenko T, Mansson G, Matvijenko O, Holmgren L. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol. 2001;152(6):1247-1254.
38. Tarui T, Miles LA, Takada Y. Specific interaction of angiostatin with integrin alpha (v)beta(3) in endothelial cells. J Biol Chem. 2001;276(43):39562-39568.
39. Chen YH, Wu HL, Li C, et al. Anti-angiogenesis mediated by angiostatin K1-3, K1-4 and K1-4.5: involvement of p53, FasL, AKT and mRNA deregulation. Thromb Haemost. 2006;95(4):668-677.
40. Chung AW, Hsiang YN, Matzke LA, McManus BM, van Breemen C, Okon EB. Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature. Circ Res. 2006;99(2):140-148.
41. Kang HY, Shim D, Kang SS, Chang SI, Kim HY. Protein kinase B inhibits endostatin-induced apoptosis in HUVECs. J Biochem Mol Biol. 2006;39(1):97-104.
42. Dhanabal M, Ramchandran R, Waterman MJ, et al. Endostatin induces endothelial cell apoptosis. J Biol Chem. 1999;274(17):11721-11726.
43. Rehn M, Veikkola T, Kukk-Valdre E, et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A. 2001;98(3):1024-1029.
44. Shichiri M, Hirata Y. Antiangiogenesis signals by endostatin. FASEB J. 2001;15 (6):1044-1053.
45. Kim YM, Hwang S, Pyun BJ, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem. 2002;277(31):27872-27879.
46. Abdollahi A, Hahnfeldt P, Maercker C, et al. Endostatin's antiangiogenic signaling network. Mol Cell. 2004;13(5):649-663.
47. Abdollahi A, Hlatky L, Huber PE. Endostatin: the logic of antiangiogenic therapy. Drug Resist Updat. 2005;8(1-2):59-74.
48. Portik-Dobos V, Anstadt MP, Hutchinson J, Bannan M, Ergul A. Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes. 2002;51(10):3063-3068.
49. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000;1477(1-2):267-283.